NASDAQ:CTMX
CytomX Therapeutics Stock News
$1.67
-0.0600 (-3.47%)
At Close: Apr 19, 2024
CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Should You Buy?
04:47pm, Thursday, 29'th Jul 2021
CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
08:00am, Thursday, 29'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi
Here's Why CytomX Therapeutics (CTMX) is Poised for a Turnaround After Losing 15.8% in 4 Weeks
11:36am, Wednesday, 14'th Jul 2021
CytomX Therapeutics (CTMX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q1 2021 Results - Earnings Call Transcript
04:31pm, Sunday, 09'th May 2021
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q1 2021 Results - Earnings Call Transcript
CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021
08:00am, Thursday, 29'th Apr 2021
SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of invest
CytomX Therapeutics Announces New Employment Inducement Grants
04:01pm, Wednesday, 14'th Apr 2021
SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of inve
Co-Diagnostics, DocuSign, Dow, Nomura, Sea and More Monday Afternoon Analyst Calls
11:47am, Monday, 29'th Mar 2021
With the trading day about halfway over, the broad markets were pushing lower. The Dow Jones industrial average and S&P 500 were only down slightly to start the week, while the Nasdaq faced the worst
CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021
08:00am, Wednesday, 24'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of inve
Moving Average Crossover Alert: CytomX Therapeutics (CTMX)
06:49am, Tuesday, 02'nd Mar 2021
CytomX Therapeutics (CTMX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2020 Results - Earnings Call Transcript
10:39pm, Wednesday, 24'th Feb 2021
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2020 Results - Earnings Call Transcript
CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences
08:00am, Monday, 22'nd Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of inves
CytomX Therapeutics Announces New Employment Inducement Grant
08:00am, Friday, 19'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi
CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
08:00am, Wednesday, 17'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi
UPDATE - CytomX Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
08:19am, Wednesday, 03'rd Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming live
CytomX Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
08:00am, Wednesday, 03'rd Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming live
